The SEC filings page for OnKure Therapeutics, Inc. (OKUR) provides access to the company’s official regulatory disclosures as a clinical-stage biopharmaceutical issuer listed on the Nasdaq Global Market. These documents offer detailed information about its precision oncology programs, financial condition, and capital markets activities, complementing the high-level descriptions found in press releases.
Through its periodic reports on Forms 10-K and 10-Q, OnKure describes its focus on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by current therapies. These filings expand on the company’s strategy around PI3Kα-targeted programs, including its lead candidate OKI-219 and its PI3Kα pan-mutant and other discovery-stage efforts, and include sections such as “Risk Factors” that outline scientific, clinical, regulatory, and financial risks.
Current reports on Form 8-K capture material events between periodic filings. For example, OnKure has filed 8-Ks to report quarterly financial results and to disclose entry into a sales agreement with Leerink Partners LLC for an at-the-market offering program of its Class A common stock. That agreement allows the company, subject to specified parameters and an effective shelf registration statement on Form S-3, to sell shares through Leerink Partners acting as sales agent, with compensation based on a percentage of gross proceeds.
On this page, users can review new and historical SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and registration statements such as Form S-3 referenced in the at-the-market program. Stock Titan’s tools apply AI-powered summaries to help explain the contents of lengthy filings, highlight key items like clinical development updates, capital raising arrangements, and risk disclosures, and make it easier to track how OnKure’s regulatory narrative evolves over time.
OnKure Therapeutics, Inc. director Andrew John Phillips received a grant of stock options covering 22,350 shares of Class A common stock at an exercise price of $4.14 per share. The options expire on August 6, 2036 and vest 100% on the earlier of June 4, 2027 or the day prior to the company’s next annual meeting of stockholders, contingent on his continued service. Following this award, he holds options on 22,350 shares.
OnKure Therapeutics director Isaac Manke reported equity compensation and option repricing activity involving stock options for Class A Common Stock. On August 7, 2026 he received a grant of 300,000 stock options with an exercise price of $4.14 per share, expiring on August 6, 2036. One quarter of these options vests on February 24, 2027 and the remainder vests in equal monthly installments over the following 36 months, contingent on continued service. On the same date, 15,300 options with an original exercise price of $18.20 per share expiring October 3, 2034 were returned to the issuer and replaced with 15,300 repriced options at an exercise price of $4.14, with the same vesting and expiration. Under the company’s one-time Option Repricing program, if any repriced option is exercised before the end of a defined retention period, the holder must pay the original higher exercise price instead of $4.14.
OnKure Therapeutics, Inc. reported that director Valerie Malyvanh Jansen received a grant of a stock option covering 22,350 shares of Class A common stock. The option has an exercise price of $4.14 per share and expires on August 6, 2036. According to the terms, 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to OnKure’s next annual meeting of stockholders, conditioned on her continued service as a provider through the applicable vesting date. Following this award, she holds 22,350 stock options directly.
OnKure Therapeutics director Michael G. Grey received a grant of 22,350 stock options to purchase Class A common stock at an exercise price of $4.14 per share. All options vest on the earlier of June 4, 2027 or the day before the next annual stockholder meeting, subject to continued service, and expire on August 6, 2036. Following this grant, he holds 22,350 options directly.
OnKure Therapeutics, Inc. reported that director R Michael Carruthers received a grant of stock options covering 22,350 shares of Class A common stock on August 7, 2026. The options have an exercise price of $4.14 per share, expire on August 6, 2036, and will vest 100% on the earlier of June 4, 2027 or the day prior to the company’s next annual meeting of stockholders, subject to continued service.
OnKure Therapeutics, Inc. reported that President and CEO Nicholas A. Saccomano received a grant of stock options for 150,000 shares of Class A Common Stock on August 7, 2026, with an exercise price of $4.14 per share and vesting in equal monthly installments over 48 months starting September 7, 2026, subject to continued service.
The company also implemented a one-time stock option repricing effective August 7, 2026 for options with exercise prices of at least $10.00 per share. Several of the CEO’s existing options with exercise prices of $21.20, $13.99, and $18.20 per share were reported as dispositions to the issuer and regrants at an amended exercise price of $4.14 per share. Footnotes state that there was no change to the vesting schedules, expiration dates, or number of shares underlying the repriced options, and that a "Retention Period" runs from August 7, 2026 until the earlier of February 7, 2028 or a Change in Control, during which early exercise of repriced options requires payment of the original higher exercise price.
OnKure Therapeutics, Inc. reported that Chief Financial Officer Jason A. Leverone received a new option grant for 50,000 shares of Class A common stock at an exercise price of $4.14 per share, expiring in 2036. He also participated in a one-time option repricing, with previously granted options for 5,781, 5,322, and 130,611 shares surrendered to the issuer and concurrently regranted with a reduced exercise price of $4.14 per share, while maintaining the same vesting schedules, expiration dates, and number of underlying shares. Footnotes state that repriced options require paying the original higher exercise price if exercised before the end of a defined Retention Period.
OnKure Therapeutics, Inc. reported equity compensation changes for Chief Scientific Officer Dylan Hartley involving stock options on Class A Common Stock. Hartley received a new grant of 50,000 employee stock options with an exercise price of $4.14 per share, expiring on August 6, 2036; 1/48 of these options vest on September 7, 2026 and monthly thereafter, conditioned on continued service. In addition, a one-time Option Repricing effective August 7, 2026 applied to options with exercise prices at or above $10.00 held by continuing employees and certain service providers. In connection with this repricing, 137,603 options with a prior exercise price of $18.20 were reported as disposed to the issuer and a corresponding 137,603 options were granted back to Hartley with a revised exercise price of $4.14 per share, keeping the original vesting schedule (1/4 vested on June 9, 2025 and 1/48 vesting monthly thereafter), expiration date of October 3, 2034, and number of underlying shares unchanged. During a defined Retention Period starting August 7, 2026 and ending on the earlier of February 7, 2028 or a Change in Control, any early exercise of these repriced options requires paying the original higher exercise price rather than the reduced $4.14.
OnKure Therapeutics, Inc. reported multiple stock option adjustments for Chief Medical Officer Samuel Agresta effective August 7, 2026. The company implemented a one-time Option Repricing for employee options with exercise prices at or above $10.00 per share, resetting the exercise price of affected options, including Mr. Agresta’s, to $4.14 per share, the closing price of the Class A Common Stock on the effective date. There was no change to vesting schedules, expiration dates or the number of underlying shares. A Retention Period applies: if a repriced option is exercised before the earlier of February 7, 2028 or a Change in Control, the holder must pay the original, higher exercise price; otherwise the reduced $4.14 exercise price applies.
OnKure Therapeutics, Inc. is the subject of an amended Schedule 13G filed by Prosight Management, LP and related entities, together with W. Lawrence Hawkins, reporting beneficial ownership of the company’s Class A Common Stock. Prosight Management, certain Prosight funds, separate managed accounts, Prosight Partners, LLC, and Hawkins (collectively the reporting persons) may be deemed to beneficially own 978,992 shares of Class A Common Stock, representing 2.4% of the class, based on 40,395,480 shares outstanding as of May 4, 2026. The reported holdings are held with shared voting and dispositive power and no sole power. Individual fund positions include 45,771 shares (0.1%) for Prosight Fund, LP and 219,725 shares (0.5%) for Prosight Plus Fund, LP. The reporting persons include extensive disclaimers of beneficial ownership and state that ownership is 5% or less of the class.